Eukaryotic initiation factor 3C silencing inhibits cell proliferation and promotes apoptosis in human glioma

Hao,Jinmin; Wang,Zhiming; Wang,Yaowu; Liang,Zhaohui; Zhang,Xin; Zhao,Zongmao; Jiao,Baohua

doi:10.3892/or.2015.3881

Eukaryotic initiation factor 3C silencing inhibits cell proliferation and promotes apoptosis in human glioma

Authors:
- Jinmin Hao
- Zhiming Wang
- Yaowu Wang
- Zhaohui Liang
- Xin Zhang
- Zongmao Zhao
- Baohua Jiao
View Affiliations

Affiliations: Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shi Jiazhuang, Hebei 050000, P.R. China, Department of Neurosurgery, Tangshan Gongren Hospital of Hebei Medical University, Tangshan, Hebei 050000, P.R. China
Published online on: March 30, 2015 https://doi.org/10.3892/or.2015.3881
Pages: 2954-2962

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eukaryotic initiation factor 3, subunit c (eIF3c), an oncogene overexpressed in human cancers, plays an important role in cell tumorigenesis and proliferation. However, studies assessing its function in gliomas are scarce. The present study evaluated for the first time, the role of eIF3c in gliomas. Immunohistochemistry was carried out to assess eIF3c expression in 95 human glioma samples and normal brain tissues. Then, the eIF3c mRNA levels were detected in tumor and normal brain specimens by quantitative RT-PCR. In addition, eIF3c mRNA levels were assessed in four glioma cell lines (U87, U251, A172 and U373) by semi-quantitative RT-PCR. The RNA interference (RNAi) technology was employed to knock down the eIF3c gene in the U251 cells. Western blot analysis, BrdU assay and flow cytometry were used to measure eIF3c protein levels, cell proliferation, cell apoptosis and cell cycle, respectively. The eIF3c protein was overexpressed in the human glioma specimens. In agreement, the eIF3c mRNA expression levels were significantly higher in the human glioma tissues compared with the normal brain samples (P<0.0001). In addition, eIF3c mRNA was detected in all the glioma cell lines. Silencing the eIF3c gene in the U251 cells by RNAi significantly suppressed cell proliferation (P<0.01) and increased apoptosis (P<0.01). Finally, a stark decrease was observed in the G1 phase cell number (P<0.01), while the S and G2 phase cells were significantly increased (P<0.01) after eIF3c knockdown. These findings suggest that eIF3c is overexpressed in human gliomas and essential for their proliferation and survival. Therefore, inhibiting eIF3c expression may constitute an effective therapy for human glioma.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	Wakabayashi T: Clinical trial updates for malignant brain tumors. Rinsho Shinkeigaku. 51:853–856. 2011.In Japanese. View Article : Google Scholar
3	Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol1. 5(Suppl 2): ii1–ii56. 2013.
4	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ohgaki H: Epidemiology of brain tumors. Cancer Epidemiology. Springer; pp. 323–342. 2009, View Article : Google Scholar
6	Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB and Rosenfeld M: Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR and Jaeckle KA: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 9:29–38. 2007. View Article : Google Scholar
8	Grossman S, Ye X, Piantadosi S, Desideri S, Nabors L and Rosenfeld M: Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. J Clin Oncol. 27:20032009. View Article : Google Scholar
9	Zhou M, Sandercock AM, Fraser CS, Ridlova G, Stephens E, Schenauer MR, Yokoi-Fong T, Barsky D, Leary JA, Hershey JW, et al: Mass spectrometry reveals modularity and a complete subunit interaction map of the eukaryotic translation factor eIF3. Proc Natl Acad Sci USA. 105:18139–18144. 2008. View Article : Google Scholar : PubMed/NCBI
10	Sonenberg N and Hinnebusch AG: Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell. 136:731–745. 2009. View Article : Google Scholar : PubMed/NCBI
11	Li BD, Liu L, Dawson M and De Benedetti A: Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer. 79:2385–2390. 1997. View Article : Google Scholar : PubMed/NCBI
12	Lamphear BJ, Kirchweger R, Skern T and Rhoads RE: Mapping of functional domains in eukaryotic protein synthesis initiation factor 4G (eIF4G) with picornaviral proteases. Implications for cap-dependent and cap-independent translational initiation. J Biol Chem. 270:21975–21983. 1995. View Article : Google Scholar : PubMed/NCBI
13	Morley SJ, McKendrick L and Bushell M: Cleavage of translation initiation factor 4G (eIF4G) during anti-Fas IgM-induced apoptosis does not require signalling through the p38 mitogen-activated protein (MAP) kinase. FEBS Lett. 438:41–48. 1998. View Article : Google Scholar : PubMed/NCBI
14	Damoc E, Fraser CS, Zhou M, Videler H, Mayeur GL, Hershey JW, Doudna JA, Robinson CV and Leary JA: Structural characterization of the human eukaryotic initiation factor 3 protein complex by mass spectrometry. Mol Cell Proteomics. 6:1135–1146. 2007. View Article : Google Scholar : PubMed/NCBI
15	Hinnebusch AG and Lorsch JR: The mechanism of eukaryotic translation initiation: New insights and challenges. Cold Spring Harb Perspect Biol. 4:42012. View Article : Google Scholar
16	Seal SN, Schmidt A and Marcus A: Ribosome binding to inosine-substituted mRNAs in the absence of ATP and mRNA factors. J Biol Chem. 264:7363–7368. 1989.PubMed/NCBI
17	Silvera D, Formenti SC and Schneider RJ: Translational control in cancer. Nat Rev Cancer. 10:254–266. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hershey JW: Regulation of protein synthesis and the role of eIF3 in cancer. Braz J Med Biol Res. 43:920–930. 2010. View Article : Google Scholar : PubMed/NCBI
19	Sesen J, Cammas A, Scotland SJ, Elefterion B, Lemarié A, Millevoi S, Mathew LK, Seva C, Toulas C, Moyal EC, et al: Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells. Int J Mol Sci. 15:2172–2190. 2014. View Article : Google Scholar : PubMed/NCBI
20	Emmanuel R, Weinstein S, Landesman-Milo D and Peer D: eIF3c: A potential therapeutic target for cancer. Cancer Lett. 336:158–166. 2013. View Article : Google Scholar : PubMed/NCBI
21	Asano K, Kinzy TG, Merrick WC and Hershey JW: Conservation and diversity of eukaryotic translation initiation factor eIF3. J Biol Chem. 272:1101–1109. 1997. View Article : Google Scholar : PubMed/NCBI
22	Moldave K: Eukaryotic protein synthesis. Annu Rev Biochem. 54:1109–1149. 1985. View Article : Google Scholar : PubMed/NCBI
23	Rothe M, Ko Y, Albers P and Wernert N: Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am J Pathol. 157:1597–1604. 2000. View Article : Google Scholar : PubMed/NCBI
24	Scoles DR, Yong WH, Qin Y, Wawrowsky K and Pulst SM: Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum Mol Genet. 15:1059–1070. 2006. View Article : Google Scholar : PubMed/NCBI
25	Song N, Wang Y, Gu XD, Chen ZY and Shi LB: Effect of siRNA-mediated knockdown of eIF3c gene on survival of colon cancer cells. J Zhejiang Univ Sci B. 14:451–459. 2013. View Article : Google Scholar : PubMed/NCBI
26	Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM and Davis FG: Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol. 1:14–25. 1999.
27	Zhang L, Pan X and Hershey JW: Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem. 282:5790–5800. 2007. View Article : Google Scholar
28	Sherr CJ: Growth factor-regulated G1 cyclins. Stem Cells. 12(Suppl 1): 47–57. 1994.PubMed/NCBI